Glia, a pioneering force in customer interaction technology, has unveiled the first-ever responsible AI platform purpose built for financial institutions.

The offering, known as Glia Cortex, will enable financial institutions to harness the power of AI in a secure and responsible manner, revolutionising customer service and contact centre operations.

The impetus behind the development of Glia Cortex stems from the increasing demand within the financial industry for AI-driven solutions to modernise and streamline contact centre operations. However, concerns around data privacy, security, and potential risks associated with AI adoption have hindered progress in this area.

Glia is renowned for its Unified Interaction Management platform, which offers comprehensive solutions for customer engagement across various channels.

Glia Cortex represents a significant leap forward, empowering financial institutions to integrate AI seamlessly into their existing workflows while maintaining stringent safeguards for data privacy and security.

At the heart of the product are three key components: Customer AI, Agent AI, and Manager AI.

These components automate and elevate customer interactions, enhance agent productivity, and provide managers with deeper insights for better team performance and service improvements.

Service 1st Federal Credit Union has already partnered with Glia to implement Glia Cortex in their contact centre operations. Sarah Zinga, AVP of Digital Services for the credit union, attested to the benefits, stating, ““How do I improve my credit score? What is my current balance? With Glia, we have been able to leverage AI to help us automate these simple calls and free up our agents’ time for when the human touch is really needed, and ultimately provide the best member experience for what our Service 1st members expect.”

This launch underscores Glia’s commitment to innovation in the financial services industry, following recent advancements such as Unified Interaction Management and generative AI solutions.

Jay Choi, CPO for Glia, explained, “Financial institutions are looking to AI to modernise and create efficiencies in their contact centres, however they have been rightfully cautious as significant questions around safety, privacy, and business and reputational risks associated with adopting AI remain. Glia Cortex unleashes the benefits of AI and generative AI while maintaining proper, steady guardrails to keep data private and secure. We’ve made it possible to deploy AI without introducing risk, providing responsible technology that institutions and their customers can trust.”

Source: fintech.global

The post Glia launches first responsible AI platform purpose built for financial institutions appeared first on HIPTHER Alerts.

The regulatory approval process with the U.S. Food and Drug Administration has commenced for Innocan’s LPT-CBD release technology, marking a key step in the advancement of non-opioid pain management

HERZLIYA, Israel and CALGARY, AB, May 21, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce significant advancements in the regulatory process for its Liposome-Cannabidiol (LPT-CBD) technology, which provides an innovative solution in non-opioid pain management. The U.S. Food and Drug Administration (“FDA”) has granted Innocan an Investigational New Drug (“IND”) number and approved an initial meeting with the Company to discuss the strategic path forward.

The meeting with the FDA has been set for July 31, 2024, where Innocan will present its preclinical results and proposed clinical development plan. This meeting is key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain.

“We are very pleased with this crucial step towards launching our IND program for LPT-CBD in the United States,” commented Iris Bincovich CEO of Innocan Pharma. “This upcoming FDA consultation is pivotal, poised to set the stage for our clinical trials and drive forward our mission to revolutionize pain management. We look forward to the FDA reviewing our development program and providing us with guidance on our advancement to human clinical trials.”

Continued Iris Bincovich, CEO, “I thank Prof. Chezy Barenholz and Dr. Ahuva Cern of the Hebrew University of Jerusalem, renowned experts in liposome research, for their continued efforts providing strong supportive data on LPT-CBD, enabling our upcoming engagement with FDA.”

LPT therapy, which requires only one single monthly subcutaneous injection, offers a groundbreaking alternative to opioid-based approaches. Addressing the critical opioid crisis, where, according to the U.S. Centers for Disease Control and Prevention, over three-quarters of drug overdose deaths in the U.S. involve opioids, Innocan’s LPT-CBD presents a compelling, life-saving alternative. In multiple pre-clinical trials, Innocan’s therapy has shown consistent efficacy of its LPT-CBD injectable treatment, through prolonged and controlled release of CBD in animals with chronic pain conditions.

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/fda-has-granted-innocan-pharma-a-meeting-date-for-lpt-cbd-for-chronic-pain-302151667.html

As the inaugural London conference commenced today, attendees heard from industry experts who shed light on Revenue Generation with Blockchain

LONDON, May 21, 2024 /PRNewswire/ — Attendees at the London Blockchain Conference experienced an enlightening first day, kickstarting with informative and thought-provoking speakers, discussing a wide range of topics involving Digital Currency and government policy, trust economy, carbon offset derivatives using blockchain and smart contracts. 

Day 1 of the conference focused on ‘Rev-gen with Blockchain’. The agenda was filled with engaging sessions and discussions that delved into various topics like the Evolution of Web 3 and its impact on the Finance Sector. Attendees also had the opportunity to explore the transformative potential of blockchain technology in areas such as data integrity, accountability, and trust for customers and users. Other notable sessions shed light on the revolutionary role of blockchain in combating counterfeit goods, stable coins, and the Future of Blockchain tokens. 

Throughout the day attendees heard from distinguished speakers who brought their expertise to the forefront.

Blockchain 101 session by Connor Murray, Director of Stewardship at BSV Association who opened the conference by explaining how blockchain technology introduces a new way of interacting with applications and services that have become integral to our digitally connected world.

The keynote speaker for Day 1 was Scott Galloway, Professor of Marketing at NYU Stern School of Business /Entrepreneur who shared his predictions on future trends, analysing the economy, Web3 ecosystem and AI’s transformative potential. He highlighted the products and trends that are receiving too much vs too little attention and investment.

Cybersecurity Future: Blockchain’s Role in Enhanced Security – a panel moderated by John Velossariis, Founder & Director, Otranto Limited, with speakers Joseph Kearney, Research Associate, University of Kent / Block Sphere, and Robert Huber, Tech Lead, Veridat, where they discussed blockchain’s impact on cybersecurity, including decentralised identity management, supply chain security, smart contracts, and DDoS attack defences.

How Teranode delivers blockchain scaling for Enterprise use – Siggi Oskarsson, Director of Teranode at BSV Blockchain, Jordan Kramsky, Solutions Architect at AWS and Behrad Babaee, Principal Architect at Aerospike discussed the pivotal role of Teranode in driving enterprise-level adoption of the BSV blockchain and is poised to revolutionise the blockchain landscape and unlock new possibilities for businesses worldwide.

Owen Vaughan, Chief Scientist Officer at nChain in his session titled, ‘What if your blockchain is different to mine?’, explained the role of Web3 and Blockchain and building a decentralised online ecosystem. He also presented nChain’s Universal Blockchain Assets (UBA) Wallet for interoperable blockchain tokens across other chains.

Tokenisation and the Wine Industry – Steven Bacci, Principal Worldwide Specialist Solutions Architect, AWS and David Garrett, Managing Partner, dVIN discussed how blockchain enhances transparency, and security, offers anti-fraud solutions, and supply chain efficiency and fosters a global community of wine lovers and producers. They also highlighted how dVIN leverages AWS-managed blockchain for innovation and market acceleration.

Solving Blockchain’s Interoperability Challenges – Moderated by Becky Liggero, Reporter, Producer and Host at Coingeek, the panellists Irina Benfrid, B2B Partnerships Lead, Rubic Finance, Clem Chambers, CEO, Online Blockchain, Evelyn Nomaya, PhD Researcher, Trinity College and Ty Everett, Founding President, Project Babbage, focused on solving blockchain’s interoperability challenges and how addressing these interoperability issues is paramount for unleashing the full potential of blockchain technology.  

Establishing Trust in AI: Blockchain – Scott Zoldi, Chief Analytics Officer at FICO, highlighted the critical role of blockchain in enforcing and proving Responsible AI practices. He stressed that the responsible use of AI is vital to society and must go beyond just pledges and ethics committees to ensure genuine accountability.

Please register here if you would like to attend or listen to any of the sessions today. 

About the London Blockchain Conference

NETWORK. LEARN. ENGAGE. 

At the London Blockchain Conference, we show how Blockchain will change the world and help people see another way to manage data, build scalable on-chain solutions and achieve great things. We do this by creating valuable, insightful, and engaging events that educate and inform, allowing you to connect and network to build strong business relationships. Our conference is the best avenue to see blockchain innovations, ecosystem announcements, product launches, technology updates, keynote speeches, panels, and fireside chats from blockchain leaders. Join us and experience it for yourself. 

View original content:https://www.prnewswire.co.uk/news-releases/london-blockchain-conference-day-1-highlights-302151978.html